Telomerase: An exploration toward the end of cancer

Indian Journal of Dental Research

Volumn 28, Issue 5, 2017, Pages 574-584

  Popli, Deepika Bablani ^a   Sircar, Keya ^a   Chowdhry, Aman ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

hTR; human telomerase reverse transcriptase; human telomerase RNA component; oral cancer; oral squamous cell carcinoma; reverse transcriptase; reverse transcriptase catalytic protein; telomerase; telomerase RNA component

Indexed keywords

TELOMERASE;

CELL PROLIFERATION; ENZYMOLOGY; GENETICS; HUMAN; MOUTH TUMOR; PHYSIOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TELOMERE;

CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; HUMANS; MOUTH NEOPLASMS; PROGNOSIS; TELOMERASE; TELOMERE;

EID: 85032948738     PISSN: 09709290     EISSN: 19983603     Source Type: Journal    
DOI: 10.4103/ijdr.IJDR_690_16     Document Type: Review

References (44)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
2. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010;31:9-18.
3. Martínez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011;11:161-76.
4. Mocellin S, Pooley KA, Nitti D. Telomerase and the search for the end of cancer. Trends Mol Med 2013;19:125-33.
5. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
6. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55.
7. Kim RH, Kim R, Chen W, Hu S, Shin KH, Park NH, et al. Association of hsp90 to the hTERT promoter is necessary for hTERT expression in human oral cancer cells. Carcinogenesis 2008;29:2425-31.
8. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
9. Kapoor P, Kharbanda OP, Monga N, Miglani R, Kapila S. Effect of orthodontic forces on cytokine and receptor levels in gingival crevicular fluid: A systematic review. Prog Orthod 2014;15:65.
10. Raghunandan BN, Sanjai K, Kumaraswamy J, Papaiah L, Pandey B, Jyothi BM. Expression of human telomerase reverse transcriptase protein in oral epithelial dysplasia and oral squamous cell carcinoma: An immunohistochemical study. J Oral Maxillofac Pathol 2016;20:96-101.
11. Hayakawa M, Sato S, Diala I, Kodama M, Tomoeda-Mori K, Haraguchi K, et al. Screening for oral cancer using electrochemical telomerase assay. Electroanalysis 2016;28:503-7.
12. Vinothkumar V, Arunkumar G, Revathidevi S, Arun K, Manikandan M, Rao AK, et al. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. Tumour Biol 2016;37:7907-13.
13. Hayakawa M, Kodama M, Sato S, Tomoeda-Mori K, Haraguchi K, Habu M, et al. Electrochemical telomerase assay for screening for oral cancer. Br J Oral Maxillofac Surg 2016;54:301-5.
14. Hung PS, Tu HF, Kao SY, Yang CC, Liu CJ, Huang TY, et al. miR-31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes. Carcinogenesis 2014;35:1162-71.
15. Kokalj Vokac N, Cizmarevic B, Zagorac A, Zagradišnik B, Lanišnik B. An evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas. Mol Cytogenet 2014;7:5.
16. Mori K, Sato S, Kodama M, Habu M, Takahashi O, Nishihara T, et al. Oral cancer diagnosis via a ferrocenylnaphthalene diimide-based electrochemical telomerase assay. Clin Chem 2013;59:289-95.
17. Palani J, Lakshminarayanan V, Kannan R. Immunohistochemical detection of human telomerase reverse transcriptase in oral cancer and pre-cancer. Indian J Dent Res 2011;22:362.
18. Abrahao AC, Bonelli BV, Nunes FD, Dias EP, Cabral MG. Immunohistochemical expression of p53, p16 and hTERT in oral squamous cell carcinoma and potentially malignant disorders. Braz Oral Res 2011;25:34-41.
19. Kang X, Chen W, Kim RH, Kang MK, Park NH. Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene 2009 29;28:565-74.
20. Chen HH, Yu CH, Wang JT, Liu BY, Wang YP, Sun A, et al. Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan. Oral Oncol 2007;43:122-9.
21. Dorji T, Monti V, Fellegara G, Gabba S, Grazioli V, Repetti E, et al. Gain of hTERC: A genetic marker of malignancy in oral potentially malignant lesions. Hum Pathol 2015;46:1275-81.
22. Miyazaki Y, Yoshida N, Nozaki T, Inoue H, Kikuchi K, Kusama K. Telomerase activity in the occurrence and progression of oral squamous cell carcinoma. J Oral Sci 2015;57:295-303.
23. Zhao T, Hu F, Qiao B, Chen Z, Tao Q. Telomerase reverse transcriptase potentially promotes the progression of oral squamous cell carcinoma through induction of epithelial-mesenchymal transition. Int J Oncol 2015;46:2205-15.
24. Sainger RN, Shah FD, Telang SD, Shah PM, Patel PS. Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. Cancer Biomark 2009;5:189-95.
25. Pannone G, De Maria S, Zamparese R, Metafora S, Serpico R, Morelli F, et al. Prognostic value of human telomerase reverse transcriptase gene expression in oral carcinogenesis. Int J Oncol 2007;30:1349-57.
26. Sainger RN, Telang SD, Shukla SN, Patel PS. Clinical significance of telomere length and associated proteins in oral cancer. Biomark Insights 2007;2:9-19.
27. Tian X, Dai S, Sun J, Jiang S, Sui C, Meng F, et al. Bufalin induces mitochondria-dependent apoptosis in pancreatic and oral cancer cells by downregulating hTERT expression via activation of the JNK/p38 pathway. Evid Based Complement Alternat Med 2015;2015:546210.
28. Liu X, Huang H, Wang J, Wang C, Wang M, Zhang B, et al. Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 2011;82:17-23.
29. McCaul JA, Gordon KE, Minty F, Fleming J, Parkinson EK. Telomere dysfunction is related to the intrinsic radio-resistance of human oral cancer cells. Oral Oncol 2008;44:261-9.
30. Freier K, Pungs S, Flechtenmacher C, Bosch FX, Lichter P, Joos S, et al. Frequent high telomerase reverse transcriptase expression in primary oral squamous cell carcinoma. J Oral Pathol Med 2007;36:267-72.
31. Hayflick L. Mortality and immortality at the cellular level. A review. Biochemistry (Mosc) 1997;62:1180-90.
32. Cunningham AP, Love WK, Zhang RW, Andrews LG, Tollefsbol TO. Telomerase inhibition in cancer therapeutics: Molecular-based approaches. Curr Med Chem 2006;13:2875-88.
33. Kumar SK, Zain RB, Ismail SM, Cheong SC. Human telomerase reverse transcriptase expression in oral carcinogenesis - A preliminary report. J Exp Clin Cancer Res 2005;24:639-46.
34. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003;114:241-53.
35. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
36. Bablani Popli D, Sircar K, Chowdhry A, Rani V. Role of heat shock proteins in oral squamous cell carcinoma: A systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:366-71.
37. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 2000;97:4796-801.
38. Vonderheide RH. Universal tumor antigens for cancer vaccination: Targeting telomerase for immunoprevention. Discov Med 2007;7:103-8.
39. Liu JP, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta 2010;1805:35-42.
40. Carpenter EL, Vonderheide RH. Telomerase-based immunotherapy of cancer. Expert Opin Biol Ther 2006;6:1031-9.
41. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002;21:674-9.
42. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173-9.
43. Uchida N, Otsuka T, Shigematsu H, Maeda M, Sugio Y, Itoh Y, et al. Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res 1999;23:1127-32.
44. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999;18:1561-7.